市場調査レポート

商品コード

1741493

皮膚がん治療薬市場：薬剤タイプ別、がんタイプ別、投与経路別、流通チャネル別、地域別

Skin Cancer Drugs Market, By Drug Type, By Cancer Type, By Route of Administration, By Distribution Channel, By Geography

出版日: 2025年03月27日
発行: Coherent Market Insights
ページ情報: 英文 150 Pages
納期: 2～3営業日

カスタマイズ可能

価格

PDF (Single User License)

USD 4,500 654,390円

レポートPDFを1名のみがご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は一度のみ可能です。印刷したもののご利用はPDFのライセンス保持者に限定されます。

PDF (Multi User License)

USD 7,000 1,017,940円

レポートPDFを7名までにてご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は7回まで可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (Enterprise User License)

USD 10,000 1,454,200円

レポートPDFを同一企業およびその子会社のすべての方に使用頂けるライセンスです。PDF内のテキスト等のコピーは可能です。PDFの印刷回数に制限はありません。印刷したもののご利用はPDFのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=145.42円

全表示
概要
目次

概要

サンプル依頼リストに入れる

皮膚がん治療薬市場は、2025年には103億米ドルと推定され、2032年には180億米ドルに達すると予測され、2025年から2032年までのCAGRは8.3%で成長すると予測されます。

レポート範囲		レポート詳細
基準年	2024年	2025年の市場規模	103億米ドル
実績データ	2020年～2024年	予測期間	2025年～2032年
予測期間：2025年～2032年 CAGR：	8.30%	2032年の価値予測	180億米ドル

皮膚がんは、皮膚細胞を侵すがんの一種で、主に太陽や日焼けベッドからの紫外線（UV）への曝露によって引き起こされます。世界的に最も罹患率の高いがんのひとつであり、その罹患率は年々増加しています。この増加傾向に対抗するため、製薬会社は皮膚がん治療薬の開発と技術革新に注力しています。

市場力学：

皮膚がん治療薬市場は、主に世界の皮膚がん罹患率の上昇によって牽引されています。紫外線への過剰な曝露、ライフスタイルの変化、高齢化などの要因が、この疾患の有病率上昇に寄与しています。さらに、治療介入の進歩や標的療法の導入が市場の成長をさらに促進しています。

しかし、市場拡大を妨げる課題もいくつかあります。高い薬剤開発コストと厳しい規制要件は、新規参入企業にとって大きな障壁となっています。さらに、特定の薬剤に伴う副作用や代替治療オプションの存在が、市場成長の抑制要因となっています。

こうした課題にもかかわらず、市場には成長の機会がいくつかあります。研究開発活動への投資の増加や、製薬企業と研究機関の共同研究は、技術革新と新規治療オプションの導入を促進すると予想されます。さらに、個別化医療への注目の高まりと併用療法の使用は、市場拡大の可能性をもたらします。

本調査の主な特徴

本レポートでは、世界の皮膚がん治療薬市場を詳細に分析し、2024年を基準年とした予測期間（2025年～2032年）の市場規模および年間平均成長率（CAGR%）を掲載しています。
また、さまざまなセグメントにわたる潜在的な収益機会を明らかにし、この市場の魅力的な投資提案マトリクスについて解説しています。
また、市場促進要因、抑制要因、機会、新製品の上市や承認、市場動向、地域別の展望、主要企業が採用する競争戦略などに関する重要な考察も提供しています。
企業ハイライト、製品ポートフォリオ、主要なハイライト、財務実績、戦略などのパラメータに基づいて、世界の皮膚がん治療薬市場の主要企業プロファイルを掲載しています。
本レポートからの洞察により、マーケティング担当者や企業の経営陣は、将来の製品発売、タイプアップ、市場拡大、マーケティング戦術に関する情報に基づいた意思決定を行うことができます。
皮膚がん治療薬の世界市場レポートは、投資家、サプライヤー、製品メーカー、流通業者、新規参入者、財務アナリストなど、この業界の様々な利害関係者に対応しています。
利害関係者は、世界の皮膚がん治療薬市場の分析に使用される様々な戦略マトリックスを通じて、意思決定を容易にすることができます。

企業プロファイル
- Novartis
- Merck
- Roche
- Amgen
- Pfizer
- Sun Pharma
- Bristol-Myers Squibb
- AstraZeneca
- Johnson &Johnson
- Valeant
- Daiichi Sankyo
- Takeda Pharmaceutical
株式会社
- LEO Pharma
- Mylan NV
- Sanofi
- Regeneron
- Eli Lilly
- Bayer
- Gilead Sciences
- Astellas Pharma

第11章セクション

参考文献
調査手法
出版社について

Product Code: CMI6345

Skin Cancer Drugs Market is estimated to be valued at USD 10.3 Bn in 2025 and is expected to reach USD 18.00 Bn by 2032, growing at a compound annual growth rate (CAGR) of 8.3% from 2025 to 2032.

Report Coverage		Report Details
Base Year:	2024	Market Size in 2025:	USD 10.3 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2025 To 2032
Forecast Period 2025 to 2032 CAGR:	8.30%	2032 Value Projection:	USD 18.00 Bn

Skin cancer is a type of cancer that affects the skin cells and is primarily caused by exposure to ultraviolet (UV) radiation from the sun or tanning beds. It is one of the most prevalent cancers globally, and its incidence has been increasing over the years. To combat this rising trend, pharmaceutical companies have been focusing on the development and innovation of skin cancer drugs.

Market Dynamics:

The skin cancer drugs market is primarily driven by the rising incidence of skin cancer worldwide. Factors such as excessive exposure to UV radiation, changing lifestyles, and an aging population contribute to the increasing prevalence of the disease. Moreover, advancements in therapeutic interventions and the introduction of targeted therapies have further fueled market growth.

However, there are several challenges that hinder the market's expansion. High drug development costs and stringent regulatory requirements pose significant barriers for new entrants. Additionally, adverse side effects associated with certain drugs and the availability of alternative treatment options act as restraining factors for market growth.

Despite these challenges, the market presents several opportunities for growth. Increasing investments in research and development activities, along with collaborations between pharmaceutical companies and research institutions, are expected to drive innovation and the introduction of novel treatment options. Moreover, the growing focus on personalized medicine and the use of combination therapies offer potential avenues for market expansion.

Key features of the study:

This report provides in-depth analysis of the global skin cancer drugs market, and provides market size (US$ Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global skin cancer drugs market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Novartis, Merck, Roche, Amgen, Pfizer, Sun Pharma, Bristol-Myers Squibb, AstraZeneca, Johnson & Johnson, Valeant, and others
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global skin cancer drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global skin cancer drugs market

Detailed Segmentation:

By Type
- Melanoma Drugs
- Non-Melanoma Skin Cancer Drugs
- Actinic Keratosis Drugs
- Others
By Route of Administration
- Topical
- Oral
- Injectable
- Others
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Others
By Mechanism of Action
- Chemotherapy
- Targeted Therapy
- Immunotherapy
- Photodynamic Therapy
- Others
By Geography
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Company Profiles
- Novartis
- Merck
- Roche
- Amgen
- Pfizer
- Sun Pharma
- Bristol-Myers Squibb
- AstraZeneca
- Johnson & Johnson
- Valeant
- Daiichi Sankyo
- Takeda
- LEO Pharma
- Mylan
- Sanofi
- Regeneron
- Eli Lilly
- Bayer
- Gilead Sciences
- Astellas Pharma

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snippet, By Drug Type
- Market Snippet, By Cancer Type
- Market Snippet, By Route of Administration
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Increasing incidence of skin cancers
- High costs of targeted therapies
- Combination therapies
Key Highlights
Regulatory Scenario
Recent Trends
Product Launches/Approvals
PEST Analysis
PORTER's Analysis
Mergers, Acquisitions, and Collaborations

4. Global Skin Cancer Drugs Market - Impact of Coronavirus (COVID-19) Pandemic

COVID-19 Epidemiology
Supply Side and Demand Side Analysis
Economic Impact

5. Global Skin Cancer Drugs Market, By Drug Type, 2020-2032, (US$ Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Chemotherapy Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Targeted Therapy Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Immunotherapy Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Hormone Therapy Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Others (Photodynamic Therapy, Cryotherapy and Others)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)

6. Global Skin Cancer Drugs Market, By Cancer Type, 2020-2032, (US$ Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Basal cell carcinoma
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Squamous cell carcinoma
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Melanoma
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Others (Kaposi's sarcoma, Mycosis fungoides and Others)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)

7. Global Skin Cancer Drugs Market, By Route of Administration, 2020-2032, (US$ Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Topical
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Injectable
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Others (Surgical procedures, radiation therapy and Others)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)

8. Global Skin Cancer Drugs Market, By Distribution Channel, 2020-2032, (US$ Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)

9. Global Skin Cancer Drugs Market, By Region, 2020-2032, (US$ Bn)

Introduction
- Market Share Analysis, By Sub-region, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, For Sub-region, 2021 -2032
- Country Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
  - Brazil
  - Argentina
  - Mexico
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
  - Germany
  - U.K.
  - Spain
  - France
  - Italy
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Sub-region, 2020-2032,(US$ Bn)
  - GCC
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Sub-region, 2020-2032,(US$ Bn)
  - South Africa
  - North Africa
  - Central Africa

10. Competitive Landscape

Company Profile
- Novartis
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
- Merck
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
- Roche
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
- Amgen
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
- Pfizer
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
- Sun Pharma
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
- Bristol-Myers Squibb
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
- AstraZeneca
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
- Johnson & Johnson
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
- Valeant
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
- Daiichi Sankyo
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
- Takeda Pharmaceutical
Company Limited
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
- LEO Pharma
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
- Mylan N.V.
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
- Sanofi
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
- Regeneron
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
- Eli Lilly
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
- Bayer
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
- Gilead Sciences
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
- Astellas Pharma
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
Analyst Views

11. Section

References
Research Methodology
About us

皮膚がん治療薬市場：薬剤タイプ別、がんタイプ別、投与経路別、流通チャネル別、地域別

Skin Cancer Drugs Market, By Drug Type, By Cancer Type, By Route of Administration, By Distribution Channel, By Geography

市場力学：

本調査の主な特徴

目次

第1章調査の目的と前提条件

第2章市場の展望

第3章市場力学、規制、動向分析

第4章世界の皮膚がん治療薬市場 - コロナウイルス（COVID-19）パンデミックの影響

第5章世界の皮膚がん治療薬市場：薬剤タイプ別、2020年～2032年

第6章世界の皮膚がん治療薬市場：がんタイプ別、2020年～2032年

第7章世界の皮膚がん治療薬市場：投与経路別、2020年～2032年

第8章世界の皮膚がん治療薬市場：流通チャネル別、2020年～2032年

第9章世界の皮膚がん治療薬市場：地域別、2020年～2032年

第10章競合情勢

第11章セクション

Market Dynamics:

Key features of the study:

Detailed Segmentation:

Table of Contents

1. Research Objectives and Assumptions

2. Market Purview

3. Market Dynamics, Regulations, and Trends Analysis

4. Global Skin Cancer Drugs Market - Impact of Coronavirus (COVID-19) Pandemic

5. Global Skin Cancer Drugs Market, By Drug Type, 2020-2032, (US$ Bn)

6. Global Skin Cancer Drugs Market, By Cancer Type, 2020-2032, (US$ Bn)

7. Global Skin Cancer Drugs Market, By Route of Administration, 2020-2032, (US$ Bn)

8. Global Skin Cancer Drugs Market, By Distribution Channel, 2020-2032, (US$ Bn)

9. Global Skin Cancer Drugs Market, By Region, 2020-2032, (US$ Bn)

10. Competitive Landscape

11. Section

皮膚がん治療薬市場：薬剤タイプ別、がんタイプ別、投与経路別、流通チャネル別、地域別

Skin Cancer Drugs Market, By Drug Type, By Cancer Type, By Route of Administration, By Distribution Channel, By Geography

市場力学：

本調査の主な特徴

目次

第1章 調査の目的と前提条件

第2章 市場の展望

第3章 市場力学、規制、動向分析

第4章 世界の皮膚がん治療薬市場 - コロナウイルス（COVID-19）パンデミックの影響

第5章 世界の皮膚がん治療薬市場：薬剤タイプ別、2020年～2032年

第6章 世界の皮膚がん治療薬市場：がんタイプ別、2020年～2032年

第7章 世界の皮膚がん治療薬市場：投与経路別、2020年～2032年

第8章 世界の皮膚がん治療薬市場：流通チャネル別、2020年～2032年

第9章 世界の皮膚がん治療薬市場：地域別、2020年～2032年

第10章 競合情勢

第11章 セクション

Market Dynamics:

Key features of the study:

Detailed Segmentation:

Table of Contents

1. Research Objectives and Assumptions

2. Market Purview

3. Market Dynamics, Regulations, and Trends Analysis

4. Global Skin Cancer Drugs Market - Impact of Coronavirus (COVID-19) Pandemic

5. Global Skin Cancer Drugs Market, By Drug Type, 2020-2032, (US$ Bn)

6. Global Skin Cancer Drugs Market, By Cancer Type, 2020-2032, (US$ Bn)

7. Global Skin Cancer Drugs Market, By Route of Administration, 2020-2032, (US$ Bn)

8. Global Skin Cancer Drugs Market, By Distribution Channel, 2020-2032, (US$ Bn)

9. Global Skin Cancer Drugs Market, By Region, 2020-2032, (US$ Bn)

10. Competitive Landscape

11. Section

第1章調査の目的と前提条件

第2章市場の展望

第3章市場力学、規制、動向分析

第4章世界の皮膚がん治療薬市場 - コロナウイルス（COVID-19）パンデミックの影響

第5章世界の皮膚がん治療薬市場：薬剤タイプ別、2020年～2032年

第6章世界の皮膚がん治療薬市場：がんタイプ別、2020年～2032年

第7章世界の皮膚がん治療薬市場：投与経路別、2020年～2032年

第8章世界の皮膚がん治療薬市場：流通チャネル別、2020年～2032年

第9章世界の皮膚がん治療薬市場：地域別、2020年～2032年

第10章競合情勢

第11章セクション